Innoveren Scientific, Inc. financial data

Symbol
IVRN on OTC
Location
151 W4 Th St, Ste 223, Cincinnati, OH
State of incorporation
Nevada
Fiscal year end
December 31
Former names
H-CYTE, INC. (to 5/22/2023), Medovex Corp. (to 6/26/2019), SpineZ (to 5/1/2014)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.68 % -32.2%
Debt-to-equity -104 % +2.94%
Return On Assets -878 % +63.9%
Operating Margin -282 % +6.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 713K shares +49.2%
Common Stock, Shares, Outstanding 712K shares +49.1%
Common Stock, Value, Issued 714 USD +49.7%
Weighted Average Number of Shares Outstanding, Basic 682K shares +141%
Weighted Average Number of Shares Outstanding, Diluted 1.07M shares +386%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.24M USD -36.2%
Research and Development Expense 1.25M USD +37828%
Operating Income (Loss) -2.88M USD +30.1%
Nonoperating Income (Expense) -377K USD +93.1%
Net Income (Loss) Attributable to Parent -3.26M USD +65.9%
Earnings Per Share, Basic 5.15 USD/shares +90.9%
Earnings Per Share, Diluted -0.73 USD/shares +90.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 544K USD +1370%
Accounts Receivable, after Allowance for Credit Loss, Current 7.24K USD -82.1%
Assets, Current 749K USD +331%
Property, Plant and Equipment, Net 15.5K USD -29.5%
Other Assets, Noncurrent 18.4K USD 0%
Assets 789K USD +228%
Accounts Payable, Current 1.26M USD +49.4%
Accrued Liabilities, Current 1.51M USD +23.3%
Contract with Customer, Liability, Current 60.9K USD -89.5%
Liabilities, Current 9.66M USD +44.3%
Operating Lease, Liability, Noncurrent 12.2K USD -89%
Liabilities 11.7M USD +39.2%
Retained Earnings (Accumulated Deficit) -61.1M USD -5.63%
Stockholders' Equity Attributable to Parent -10.9M USD -33.6%
Liabilities and Equity 789K USD +228%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -362K USD +59.1%
Net Cash Provided by (Used in) Financing Activities 478K USD -57.7%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 712K shares +49.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 116K USD -52.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 70K USD +4981%
Operating Lease, Liability, Current 12.8K USD -85.5%
Additional Paid in Capital 49.8M USD +1.05%
Share-based Payment Arrangement, Expense 61K USD -62.3%
Interest Expense 150K USD +108%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%